Q2 2023
Released Aug 9, 2023, after the close
10-Q filed Aug 9, 2023, 40 days after period end · 0001493152-23-027337
Q2 2023 · 10-Q
Revenue$3.55M$3.55M +24.4% vs Q2 2022−4.1% vs Q1 2023
Net Income-$433.00K-$433.00K N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.04-$0.04 N/M vs Q2 2022N/M vs Q1 2023
Gross Profit$2,079,000+49.0%
Operating Income-$435,000N/M
Operating Cash Flowderived$226,000N/M
Margins · derived
Gross margin58.6%+9.7 pt vs Q2 2022
Operating margin-12.3%+16.3 pt vs Q2 2022
Net margin-12.2%+27.7 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $3.55M | $2.85M | $2.27M | $1.58M |
| Net Income | -$433.00K | -$1.14M | -$1.13M | -$1.66M |
| EPS Diluted | -$0.04 | -$0.12 | -$0.12 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR